AB
The company develops anti-inflammatory, anti-fibrotic, and anti-neovascular therapies targeting CSF1R to treat diseases with significant unmet medical needs. Their technology aims to provide healthcare professionals with effective treatment options for conditions that currently lack adequate therapeutic solutions.
Updated 4 months ago
Funding
$39M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The company develops anti-inflammatory, anti-fibrotic, and anti-neovascular therapies targeting CSF1R to treat diseases with significant unmet medical needs. Their technology aims to provide healthcare professionals with effective treatment options for conditions that currently lack adequate therapeutic solutions.